Beijing Mandates Bold New Push for AI Drug Discovery, Surgical Robots
Listen to the full version
Beijing authorities released a sweeping set of policies on April 7 aimed at transforming the city into a global powerhouse for biomedical innovation, specifically targeting advancements in artificial intelligence-driven drug discovery, high-tech surgical robots, and global clinical trials.
Spearheaded by the municipal medical security bureau and eight other government departments, the Several Measures to Support the High-Quality Development of Innovative Medicine (2026 Edition) introduces 32 specific tasks spanning the entire pharmaceutical chain — from initial research and clinical trials to regulatory approval, commercial distribution, and frontline hospital application.
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
- DIGEST HUB
Digest Hub
Back
- Beijing released 32 measures on April 7 (2026 Edition) to boost biomedical innovation in AI drug discovery, surgical robots, and global clinical trials.
- 2025 industry: 1.13T yuan ($165.34B, +6.5%); 6 drugs, 10 devices, 11 Class III AI devices (national high). Targets: 15 AI/organ-chip models, 120 int'l trials.
- Hospitals: ≥6% revenue to R&D; robot integration via insurance; 10 high-quality medical datasets for 20+ enterprises.
- PODCAST
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新